An association between lower educational attainment (EA) and an increased risk for depression has been confirmed in various western countries. This study examines whether pleiotropic genetic effects contribute to this association. Therefore, data were analyzed from a total of 9662 major depressive disorder (MDD) cases and 14 949 controls (with no lifetime MDD diagnosis) from the Psychiatric Genomics Consortium with additional Dutch and Estonian data. The association of EA and MDD was assessed with logistic regression in 15 138 individuals indicating a significantly negative association in our sample with an odds ratio for MDD 0.78 (0.75-0.82) per standard deviation increase in EA. With data of 884 105 autosomal common single-nucleotide polymorphisms (SNPs), three methods were applied to test for pleiotropy between MDD and EA: (i) genetic profile risk scores (GPRS) derived from training data for EA (independent meta-analysis on~120 000 subjects) and MDD (using a 10-fold leave-one-out procedure in the current sample), (ii) bivariate genomic-relationship-matrix restricted maximum likelihood (GREML) and (iii) SNP effect concordance analysis (SECA). With these methods, we found (i) that the EA-GPRS did not predict MDD status, and MDD-GPRS did not predict EA, (ii) a weak negative genetic correlation with bivariate GREML analyses, but this correlation was not consistently significant, (iii) no evidence for concordance of MDD and EA SNP effects with SECA analysis. To conclude, our study confirms an association of lower EA and MDD risk, but this association was not because of measurable pleiotropic genetic effects, which suggests that environmental factors could be involved, for example, socioeconomic status.
INTRODUCTION
An association between lower educational attainment (EA) and increased risk for major depressive disorder (MDD) has been confirmed in various western countries. A meta-analysis of 37 studies from mainly western countries found a 3% decrease in log odds ratio (OR) for depression per additional year of education. 1 Research of the World Mental Health Survey Initiative also found that those with high educational levels are generally at lower risk for depression in high-income countries, although Japan showed an inverted association. 2 The International Consortium of Psychiatric Epidemiology found a negative correlation in the United States and the Netherlands, 3 which was confirmed in a recent study in the Netherlands. 4 The association of lower EA and increased MDD risk could result from multiple, not necessarily independent, effects: including causal, environmental or pleiotropic genetic effects. Lower EA could lead to an increased MDD risk (social causation), for example, via stress associated with lower socioeconomic status, or via less effective coping strategies or unhealthier lifestyles among those with lower EA. 5, 6 However, lower EA could also be the result of MDD vulnerability, for example, when the onset of MDD is at an early age before educational goals would have been achieved. Alternatively, a third factor could be in play impacting on both, such as personality characteristics or less developed cognitive abilities, causing lower EA and increased risk for MDD. Such a third factor could also consist of pleotropic genetic effects (or linkage disequilibrium between effective variants) resulting in genetic correlation (the part of the phenotypic correlation caused by shared additive genetic effects), because EA 7 and MDD [8] [9] [10] both have a confirmed genetic basis.
It is relevant to understand the mechanisms of the association between lower EA and MDD, because this can have important implications for prevention strategies of MDD and its consequences. When lower EA would increase MDD risk, the responsible mechanisms should be studied and subsequently addressed, for example, by providing psychoeducation about these mechanisms to those with lower EA. However, when shared genetic effects would link EA and MDD, no responsible mechanisms can be addressed, and prevention would be restricted to general advice to prevent MDD.
The possible impact of pleiotropic genetic effects on lower EA and increased MDD risk has not received much study. We are aware of three such studies, of which two find a substantial negative genetic correlation between EA and cross-sectional measures of depressive symptoms obtained via self-report questionnaires. 11, 12 One study used DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition)-based diagnosis of MDD with a twin design, and generally supported the social causation model and found only a small genetic correlation. 5 To the best of our knowledge, no study combined DSM-IV-based diagnosis and genome-wide single-nucleotide polymorphisms (SNP) data to test for pleiotropic genetic effects between lower EA and MDD risk.
The current study was conducted to test for pleiotropic genetic effects between lower EA and MDD diagnoses in a large sample of 25 000 subjects from the Psychiatric Genomics Consortium (PGC) 13 with additional Estonian and Dutch data. We applied the following SNP-based methods: genetic profile risk score (GPRS) analyses, bivariate genomic-relationship-matrix restricted maximum likelihood (GREML) analysis and SNP effect concordance analysis (SECA).
MATERIALS AND METHODS Subjects
Genotype and phenotype data of 10 cohort studies were combined: eight cohorts [14] [15] [16] [17] [18] [19] [20] [21] included in the PGC 13 plus two additional cohorts. The first additional cohort was from the Netherlands and combined additional independent data from the Netherlands Study of Depression and Anxiety 22 and the Netherlands Twin Registry 23 (NESDA/NTR-2). The second additional cohort was a population-based sample from Estonia (EGCUT). 24 The numbers of cases and controls per cohort are displayed in Table 1 .
MDD cases and controls
All cases (N = 9662) had a DSM-IV-or ICD-10 (10th revision of the International Classification of Diseases)-based diagnosis of MDD in lifetime according to a structured diagnostic instrument. Most controls (N = 14 949) were randomly selected from the population and screened for a lifetime history of MDD. A more detailed description of the PGC cohorts was given previously 13 and is summarized in Supplementary Table 1 . For the NESDA/ NTR-2 cohort, MDD cases were diagnosed with the DSM-IV-based CIDI (Composite International Diagnostic Interview, version 2.1), and controls scored low on various mental health screening questionnaires (NTR) 25 or had no diagnosis of a psychiatric disorder in their lifetime (NESDA). For the EGCUT (Estonian Genome Center of the University of Tartu) cohort, MDD cases were identified using ICD-10 codes F32 (depressive disorder) and/or F33 (recurrent depressive disorder), and MDD controls excluded all subjects with a lifetime ICD10 psychiatric diagnosis (category F). 24 Educational attainment EA was assessed in 7 of the 10 contributing cohorts (EGCUT, GenRED (Genetics of Recurrent Early-Onset Depression), GSK (GlaxoSmithKline), NESDA/NTR-1, NESDA/NTR-2, QIMR (Queensland Institute of Medical Research), and STAR*D (Sequenced Treatment Alternatives to Relieve Depression)). For NESDA/NTR-1 and NESDA/NTR-2, EA was defined as the years of education required for the highest diploma attained following the Dutch educational system. For QIMR and EGCUT, EA was defined as the US years of education required for the highest diploma attained following the ISCED (International Standard Classification of Education) classification. 7 For GSK, EA was defined as the number of years that school was attended. For STAR*D, EA was expressed in years of education. For GenRED, EA was assessed in controls only as the highest diploma attained and ranged from 1 to 5 labeling the following educational levels: (1) lower than high school, (2) high school, (3) some college, (4) bachelor degree and (5) higher than bachelor degree.
The EA measure was corrected per cohort for year of birth and sex, in line with the recent meta-analysis from the Social Science Genetic Association Consortium. 7 Thereby, the standardized residuals were obtained after regression of EA on sex, year of birth (YOB), YOB 2 and YOB 3 , and the interaction of sex with YOB, YOB 2 and YOB 3 . For STAR*D and GSK, YOB was not available and substituted with age. In all cohorts, EA was defined in individuals over 25 years of age only, so that they had time to Association between lower educational attainment and depression achieve their educational potential. The distribution of EA z-scores is displayed in Supplementary Figure 1 .
Genotyping, quality control and imputation
Genotyping, quality control and imputation were performed in line with previous publications and are described in detail in the Supplementary Materials. In short, quality-controlled SNPs with a minor allele frequency 40.01 from the HapMap3 reference panel 26 were imputed and yielded information on 884 105 autosomal common SNPs. With these SNPs, the genomic relationship matrix was estimated and unrelated subjects selected (with maximum pairwise genetic relationships 0.05, which is approximately equivalent to second cousins), using the GCTA software (Brisbane, Queensland, Australia). 27 All of the subsequent genetic analyses were corrected for possible confounding cohort and genotyping effects by including a categorical covariate labeling the 10 cohorts, and within cohorts the different genotyping batches, where applicable (i.e. three batches within NESDA/NTR-2, two batches within EGCUT and two batches within QIMR). Ancestry-informative principal components were based on the genomic relationship matrix and estimated with the GCTA software. 27 
Genetic profile risk scores
Preparation of the GPRS based on EA discovery results (EA-GPRS) and MDD discovery results (MDD-GPRS) is described in detail in the Supplementary Materials. In short, the procedure from Purcell et al. 28 implemented in PLINK 29 was applied. The independent EA discovery results were from the recent meta-analyses on US years of schooling from the Social Science Genetics Association Consortium (SSGAC) 7 containing around 120 000 subjects. EA-GPRS analyses were not conducted for Bonn/Mannheim, GenRED and STAR*D, because no independent discovery results were available. To obtain the MDD discovery results was slightly more elaborate, because no large MDD cohort exists that is independent of PGC. Therefore, a 10-fold leave-one-cohort-out approach was followed, and the discovery results were thus based on around 8000 cases and 12 000 controls. The GPRS were based on the same set of independent SNPs. First, the SNPs were selected with results available for all of the discovery sets. Second, this set of SNPs was pruned to a set of 76 516 independent SNPs with a maximum pairwise r 2 of 0.25 based on a sliding window of 200 SNPs with steps of 5 SNPs. 29 The EA-GPRS and MDD-GPRS were then estimated based on all SNPs up to P-value thresholds (P T ) in the respective discovery results of 0.001, 0.01, 0.1 and 1, respectively. Consequently, all GPRS with P T = 1 were based on the exact same SNPs, but GPRS with different P T were based on different sets of SNPs depending on the respective discovery results (see Supplementary Table 2 ). The GPRS were standardized per cohort to a mean of 0 and s.d. of 1 to aid interpretability of results.
Statistical analyses
The association of EA to MDD risk (phenotypic correlation) was assessed with logistic regression within EGCUT, GSK, NESDA/NTR-1 and -2, QIMR and STAR*D separately, and in the combined sample correcting for covariates labeling the cohorts.
GPRS analyses. In the first method to test for pleiotropic genetic effects, we estimated the across-trait effects of EA-GPRS on MDD and, vice versa, the effects of MDD-GPRS on EA. For comparison, we also estimated the within-trait effects of EA-GPRS on EA and MDD-GPRS on MDD. The effects of GPRS on EA and MDD were assessed with linear and logistic regression respectively. For the full sample, the effects were assessed for the GPRS based on P T of 0.001, 0.01, 0.1 and 1; for the individual cohorts, the effects were only assessed for the GPRS based on P T = 1.
The proportions of variation explained in EA and MDD were estimated as additional measures of the impact of GPRS. For EA, this proportion was derived as the R 2 of the linear regression model including the covariates and the polygenic risk score, minus the R 2 of the model including the covariates only. For MDD, Nagelkerke's pseudo R 2 were derived and corrected for the covariates by substituting the null (or intercept) model in Nagelkerke's equation for the model including the covariates (adjusted equation in Supplementary Materials). Lee et al. 30 indicated that Nagelkerke's pseudo R 2 can be biased by ascertainment, when the proportion of cases in the study sample differs from the population disease frequency. Therefore, they proposed an R 2 measure that is robust against ascertainment bias and interpretable on the liability scale. This liability R 2 was obtained by rescaling Nagelkerke's R 2 for an MDD population prevalence of K = 0.2 (see Supplementary Materials). 30 Bivariate GREML. The GREML mixed linear model method was used (i) to assess the proportion of variation in EA and MDD explained by genomewide common SNPs (SNP-h 2 ) and (ii) to assess the pleiotropic genetic effects between MDD and EA (genetic correlation), as implemented in GCTA. 27, 31, 32 The MDD SNP-h 2 was expressed on the liability scale for a population prevalence of K = 0.2 by converting the SNP-h 2 on the observed scale (controls 0; cases 1) with Equation (23) from Lee et al. 33 Bivariate GREML estimates of the genetic correlation are approximately the same on the liability scale as on the observed scale, 32 which implies that (i) its value does not depend on population disease prevalence K and (ii) that the genetic correlation between the binary MDD status and continuous EA measure could be estimated. The genetic correlation was, first, estimated with EA information from both cases and controls. This estimate could, however, potentially be confounded by case ascertainment (which may not be education independent). Therefore, the genetic correlation was estimated a second time with EA information from controls only and MDD status from both cases and controls. The GPRS and GREML analyses were corrected for sex, the first 10 (GPRS) or 20 (GREML) principal components and covariates labeling the cohorts and genotype batches. The necessity to correct for the principal components is indicated by a significant correlation between some of the GPRS with some of the principal components ( Supplementary Table 3 ).
SNP effect concordance analysis. In SECA (http://neurogenetics.qimrber ghofer.edu.au/SECA) 34 association results are analyzed, rather than individual genotyped data, to test for concordance between two traits with respect to the SNP effects significance as well as their directions. We applied SECA on the EA meta-analyses results from the SSGAC 7 and MDD association results on our own sample.
RESULTS
The overall sample consisted of 9662 patients with MDD in lifetime and 14 949 controls with a mean age of 46.2 (s.d. 15.6) and 59.4% female; information on EA was available for 5373 cases and 9765 controls (Table 1 ). In all cohorts with EA information available for both cases and controls, the phenotypic associations between EA and MDD was negative, with an overall OR of 0.78 (95% confidence interval: 0.75-0.82, P = 2.2e − 31) per standard deviation increase in EA ( Figure 1 ). This negative association was consistent for MDD cases with known age of onset 430 years. The strongest association was found in GSK with an OR of 0.45 (95% confidence interval: 0.40-0.50). When GSK was left out of the analyses, the overall association remained significant with an OR of 0.88 (95% confidence interval: 0.84-0.92). The association was comparable in male and female ( Supplementary Figure 2 ).
GPRS analyses
The GPRS had within-trait predictive effects as expected. The MDD-GPRS predicted MDD with most predictive power for the Figure 1 . Forest plot of the phenotypic association between educational attainment (EA) and major depressive disorder (MDD). The odds ratio (OR) for MDD per s.d. increase in EA is displayed for the individual cohorts, as well as for the overall sample. The ORs were estimated with logistic regression of MDD on the corrected EA z-scores, which were defined as the standardized residuals of the regression of EA on sex, year of birth (YOB), YOB 2 and YOB 3 , and the interaction of sex with YOB, YOB 2 and YOB 3 .
polygenic risk score including all SNPs (P T = 1), with an OR of 1.13 (P = 1.7e − 16) and an R 2 of 0.4% on the liability scale (Table 2a ). The EA-GPRS predicted EA also in the expected direction, again with most predictive power for GPRS including all SNPs, with a β of 0.11 (P = 2.7e − 37) and an R 2 of 1.2% (Table 2a ). However, we found no significant across-trait prediction: the MDD-GPRS did not predict EA (β = − 0.01 P = 6.7e − 2) and the EA-GPRS did not predict MDD (OR = 0.99 P = 5.9e − 1; Table 2a ). Secondary analyses, performed within all cohorts separately, indicated that the within-trait predictive effects were consistent in all cohorts, and that the lack of across-trait predictive power was also consistent for all cohorts (Table 2b ). In addition, no correlation was found between the MDD-GPRS and the EA-GPRS themselves (P T = 1; correlation coefficient of 0.006, P = 0.413). In additional analyses, across-trait predictive effects on MDD were tested for GPRS based on the SSGAC EA outcome tagging College completion (College-GPRS). 7 College completion distinguishes more in the extreme end of the EA distribution, and has a confirmed genetic basis. 7 However, no predictive effects of the College-GPRS on MDD were found (OR = 0.99, P = 0.74 for P T = 1; Supplementary  Table 4 ).
GREML analyses GREML analyses in the overall study sample generated an estimate of MDD SNP-h 2 of 0.173 (s.e. = 0.017, P o 1e − 16) on the liability scale (K = 0.2); this finding was not solely driven by one of the individual cohorts, because the MDD SNP-h 2 was estimated at consistent values when one cohort was left out at the time ( Table 3 ). The MDD SNP-h 2 was larger when expressed on the liability scale (0.173) compared with that on the observed scale (0.126), with a larger SNP-h 2 for larger values of disease frequency The impact of the GPRS, based on EA discovery results (EA-GPRS) and MDD discovery results (MDD-GPRS), on target MDD and on target EA were estimated with, respectively, logistic and linear regression, while including sex, the first 10 principal components and covariates labeling the cohorts and genotype batches. The impact on MDD was, in addition, estimated as Nagelkerke's R 2 and the R 2 on the liability scale; 30 the impact on EA as the standard R 2 of linear regression. On the overall sample, the effects were estimated for GPRS on different sets of SNPs with different thresholds of significance in the discovery set (P o0.001; Po 0.01; Po0.1; Po 1) (panel A). The impact on MDD and EA in the separate cohorts was, subsequently, estimated for the polygenic risk scores based on all SNPs (threshold Po 1) (panel B). The number of individuals included in the analyses is displayed: note that individuals from B, GE and S are excluded from the analyses with polygenic risk scores based on EA discovery results, because these cohorts were (partly) included in the discovery phase. Table 5 ). The EA SNP-h 2 was estimated at 0.124 (s.e. = 0.019, P = 2.8e − 11) when EA information in both cases and controls was taken into account (Table 3a) , and at 0.144 (s.e. = 0.030, P = 1.5e − 6) when EA information of controls only was used (Table 3b) . Again, these estimates were not solely driven by one of the individual cohorts ( Table 3 ). The genetic correlation between MDD and EA was estimated at − 0.253 (s.e. = 0.087, P = 0.004) when EA information of both cases and controls was taken into account (Table 3a) . As a correlation between genetic and environmental factors is likely to be partitioned into the genetic variance and covariance components, we explored the robustness of this estimate by limiting EA to be measured only in controls. When taking into account EA of controls only and MDD status from cases and controls, the genetic correlation dropped considerably and was no longer significantly different from 0 with an estimate of − 0.110 (s.e. = 0.105, P = 0.298; Table 3b ). In post hoc analyses, we tested if EA moderated the polygenic effects on MDD, but found no such evidence with neither GPRS nor GREML analyses (Supplementary Materials).
SNP effect concordance analysis SECA showed no evidence for genetic correlation. The primary SECA test divided the SNPs in 144 subsets based on significance of association with MDD and EA smaller than, respectively, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1.0. Not a single of these subsets contained a larger number of SNPs than expected by chance, that is, no concordance was found with respect to the MDD and EA SNP effect significances. When comparing the directions of SNP effects, only 4 of the 144 subsets showed nominally correlated directions of effect, which is not more than expected by chance (permuted empirical P-value 0.244), indicating no concordance with respect to the MDD and EA SNP effect directions.
DISCUSSION
This study tested the existence of pleiotropic genetic effects (genetic correlation) between MDD and lower EA on individual genotype data from a large sample of~25 000 subjects from western countries. To start, a strong negative phenotypic association was found with an OR for MDD of 0.78 per s.d. increase in EA, which is in line with findings from a meta-analysis of 37 studies from mainly western countries by Lorant et al. 1 Our first test for genetic correlation was negative with no across-trait predictive power of the GPRS: EA-GPRS did not predict MDD and MDD-GPRS did not predict EA. In the second test for genetic correlation, GREML analyses did not show consistent evidence for genetic correlation. The third test, SECA, also showed no evidence To estimate the robustness of these findings, the analyses were repeated leaving one cohort at the time (additional lines in upper and lower panel). The MDD SNP-h 2 was expressed on the liability scale assuming a population prevalence K of 20% (see Supplementary Table 5 for comparison of the MDD SNP-h 2 for different values of K with the SNP-h 2 on the observed scale). MDD was available for all 10 cohorts; EA was only available for cohorts E, GE, GS, N1, N2, Q and S. The analyses were corrected for sex, the first 20 principal components and a categorical covariate labeling the cohorts and genotype batches. a Explained in MDD (MDD SNP-h 2 ) and EA (EA SNP-h 2 ) by genome-wide common SNPs, as well as the genetic correlation between MDD and EA.
for concordance of EA and MDD SNP effects with respect to their significance or direction. The GPRS in our study had within-trait predictive power in line with previous findings, 7, 13 and were based on an independent EA discovery sample from the SSGAC 7 of~120 000 subjects and independent MDD leave-one-cohort-out discovery samples of 8000 cases and 12000 controls. These numbers seem adequate, but the discovery sets would ideally have been even larger, because most predictive power was still found for the GPRS including all SNPs (P T = 1), indicating that true effect SNPs were associated in the discovery sample with P-values close to 1. 28 Nevertheless, Dudbridge power calculations suggested that the EA-GPRS were well powered to predict MDD when the genetic correlation would have been around − 0.2 (Supplementary Figure  3 ). 35 Our GPRS results, therefore, indicate that a large genetic correlation between EA and MDD is unlikely, but could not exclude a small genetic correlation of around − 0.1.
We performed GREML analyses to estimate the MDD SNP-h 2 , EA SNP-h 2 and genetic correlation. The MDD SNP-h 2 found (0.17) was considerably smaller than the one previously found by Lubke et al.
(0.32), 10 which could well be because of the actual differences in SNP-h 2 across cohorts; the sample of Lubke was included in the current study as NESDA/NTR-1 and indeed had the largest contribution to the overall SNP-h 2 of all cohorts ( Table 3 ). The EA SNP-h 2 (0.14 in controls only) was of the same magnitude (o 2 s.e. difference) as the SNP-h 2 found by Rietveld et al. (0.2). 7 The GREML estimate of the genetic correlation was somewhat complicated to interpret. A significant negative genetic correlation was found (−0.25, P = 0.004) when EA information of both cases and controls was taken into account, but we fear this finding could be biased particularly in the context of genotype and environment correlation. In fact, when taking EA information of only controls into account, the estimate of genetic correlation dropped considerably and was no longer significant (−0.11, P = 0.30). However, we note that this estimate was conservative as it reduced variation in EA, and we note the negative point estimate and high standard error, showing that this analyses was underpowered to draw definitive inference. Taken together, the GREML analyses could be in line with a small genetic correlation of around − 0.1. In addition to the two methods based on individual-level genotype data, we also performed analyses on GWAS summary statistics with the recently published SECA method 34 and found no evidence for genetic correlation.
To the best of our knowledge, only three previous studies tested for a genetic correlation between MDD and EA. López-León et al. 11 used a family-based approach in 2383 subjects to find a negative genetic correlation of − 0.65 and − 0.50 between EA and self-reports of depressive symptoms based on, respectively, the Center for Epidemiologic Studies Depression Scale (CES-D) and the Hospital Anxiety and Depression Scale (HADS-D). Boardman et al. 12 also used cross-sectional CES-D assessments and found a genetic correlation of − 0.7 with GREML analyses. Mezuk et al. 5 used a twin design with depression assessed with the DSM-IVbased Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-I), and their study generally supported social causation as cause for the link between lower EA and increased MDD risk, and found only a small genetic correlation of − 0.22. 5 The studies of López-León et al. 11 and Boardman et al. 12 contrast our finding of no, or at most a small, genetic correlation, but this could be because they tested symptom reports of depressive state at a specific point in time, whereas our study tested the presence of a more clinical construct: DSM-IV-or ICD-10-based lifetime diagnosis of MDD. Indeed, our results appear in line with the findings from Mezuk et al., 5 who also used DSM-IV-based diagnoses of MDD. Furthermore, we found that the association between lower EA and MDD remained when cases with an age of first MDD onset 430 were taken into account exclusively. This indicates that it is unlikely that MDD directly causes a lowering of EA, as it can be assumed that one reaches his or her education potential before the age of 30 years, which is in line with the suggested social causation by Mezuk et al. 5 The finding that there is no, or at most a small, genetic correlation between lower EA and MDD is relevant, because this implies that non-genetic factors have an important role, and that underlying mechanisms may possibly be accessible to interventions. For example, when the social causation model would be studied in more detail, this could potentially lead to underlying clues on how lower socioeconomic status could contribute to vulnerability for MDD, or alternatively how higher socioeconomic status may buffer against vulnerability for MDD. For instance, lower socioeconomic status has shown to be associated with less healthy life styles (less physical exercise, more smoking, higher body mass index and more use of alcohol), 36, 37 less adequate medical treatment seeking behavior, 38 less knowledge about MDD 39 and higher vulnerability to experience stressful life events. 40 These factors could all contribute to increased MDD risk. However, future research should be conducted to elucidate the most important underlying mechanism as these may hint to either public or personal actions to best prevent MDD among individuals with lower EA. Yet another mechanism underlying the link between lower EA and MDD could possibly be found in a third factor other than genetic effects, such as a certain personality characteristic or less developed cognitive abilities, that causes both lower EA and increased MDD risk.
Our study has several strengths, but also some limitations. First, our study is one of the first and largest studies to test for pleiotropy between lower EA and MDD, and we used individuallevel genotype data. In addition, we used clinically relevant DSM-IV-and ICD-10-based diagnoses of MDD. Furthermore, we applied three distinct methods that essentially lead to the same conclusion. A limitation of our study is that the discovery samples of the polygenic risk score analyses were not optimally sized with maximum predictive power of the GPRS including all SNPs (P T = 1). However, this is a limitation of most current genetic studies, and we feel our discovery samples were adequately powered given the availability of relevant genetic cohorts up to date. Furthermore, the genetic basis of MDD is strong enough to study pleiotropy, as has been indicated in a previous work from the PGC that indicate a genetic correlation between MDD schizophrenia (0.43 ± 0.06) and MDD bipolar disorder (0.47 ± 0.06) with both GREML 41 and GPRS analyses. 42 Another limitation is that we could have missed pleiotropic effects among rare SNPs with an MAF o0.01. This limitation could be addressed with a family or twin study, but it would be surprising when SNPs with MAF o 0.01 would have large pleiotropic effects, while SNPs with MAF 40.01 show no such evidence.
To conclude, we did confirm a negative phenotypic association between MDD and EA, but found no evidence that this association is due to genetic factors, which indicates that a large genetic correlation between lower EA and MDD is unlikely, but does not exclude a small genetic correlation of around − 0.1. Understanding of the possible pathways between lower EA and MDD risk requires further research including twin analyses for an additional estimate of the upper bound of the genetic correlation. Nevertheless, we believe that the finding of the absence of large pleiotropic genetic effects underlying the established correlation of lower EA with increased MDD risk may be relevant, as it points to non-genetic mechanisms that may be accessible to interventions aimed at breaking this deleterious link.
